← Back to headlines
Summit Therapeutics Reports Q2 GAAP EPS of -$0.28, Beats Estimates
Summit Therapeutics released its second-quarter financial results, reporting a GAAP EPS of -$0.28, which managed to beat analyst estimates by $0.01.
23 Jul, 20:25 — 23 Jul, 20:25
Sources
Showing 1 of 1 sources
